Health Care & Life Sciences » Pharmaceuticals | Formosa Laboratories Inc.

Formosa Laboratories Inc. | Income Statement

Fiscal year is January-December. All values TWD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,474
2,496
2,597
3,189
2,539
2,688
Cost of Goods Sold (COGS) incl. D&A
2,134
1,810
1,791
1,932
1,545
1,794
Gross Income
339
687
806
1,257
995
893
SG&A Expense
414
410
480
594
617
833
EBIT
75
277
326
-
378
60
Unusual Expense
8
1
6
1
-
-
Non Operating Income/Expense
26
50
40
22
51
101
Interest Expense
27
24
33
32
22
18
Pretax Income
58
310
344
612
311
146
Income Tax
11
47
61
129
76
22
Equity in Affiliates
-
-
-
-
-
1
Consolidated Net Income
69
262
282
483
235
125
Net Income
69
262
282
483
239
177
Net Income After Extraordinaries
69
262
282
483
239
177
Net Income Available to Common
69
262
282
483
239
177
EPS (Basic)
0.97
3.10
3.31
5.48
2.61
1.85
Basic Shares Outstanding
72
85
85
88
91
95
EPS (Diluted)
0.97
2.97
3.09
5.22
2.54
1.78
Diluted Shares Outstanding
72
90
95
94
95
101
EBITDA
76
470
557
929
661
378
Non-Operating Interest Income
-
-
-
1
6
2
Minority Interest Expense
-
-
-
-
3
52

About Formosa Laboratories

View Profile
Address
No. 36 Hoping Street
Taoyuan 338 42
Taiwan
Employees -
Website http://www.formosalab.com
Updated 07/08/2019
Formosa Laboratories, Inc. engages in the research and development of biotechnology new drugs. It specializes in development, production, process, and sale of ultraviolet absorbers, cholesterol phosphate binders, vitamin D derivatives, anti-inflammatory analgesic, and central nervous system drugs. The company's products include active pharmaceutical ingredients, contract research and custom synthesis, integrated application delivery controller services, and ultraviolet filters for sunscreens and cosmetics.